miércoles, 17 de mayo de 2017

Evaluation of dosing strategy for pembrolizumab for oncology indications | Journal for ImmunoTherapy of Cancer | Full Text

Evaluation of dosing strategy for pembrolizumab for oncology indications | Journal for ImmunoTherapy of Cancer | Full Text

Biomed Central

Journal for ImmunoTherapy of Cancer

Evaluation of dosing strategy for pembrolizumab for oncology indications

  • Tomoko Freshwater,
  • Anna Kondic,
  • Malidi Ahamadi,
  • Claire H. Li,
  • Rik de Greef,
  • Dinesh de Alwis and
  • Julie A. StoneEmail author
Journal for ImmunoTherapy of Cancer20175:43
DOI: 10.1186/s40425-017-0242-5
Received: 15 September 2016
Accepted: 26 April 2017
Published: 16 May 2017



Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pembrolizumab studies; however, following availability of PK data, the need for weight-based dosing for pembrolizumab was reassessed.


A previously established population PK (popPK) model as well as exposure-response results from patients with advanced melanoma or non–small cell lung cancer (NSCLC) were used to evaluate the potential application of a fixed dosing regimen with the aim of maintaining pembrolizumab exposures within the range demonstrated to provide near maximal efficacy and acceptable safety. Individual PK exposures for the selected fixed dosing regimen from recently completed trials with head and neck cancer, NSCLC, microsatellite instability high (MSI-H) in colorectal cancer (CRC) and urothelial cancer were used to confirm acceptability. To determine whether fixed dosing would maintain exposures within the range of clinical experience, the individual AUC distributions with fixed dosing were compared with the range of exposures from the pembrolizumab doses that were evaluated in early studies (2 mg/kg Q3W, 10 mg/kg Q3W/Q2W).


Body-weight dependence of clearance was characterized by a power relationship with an exponent of 0.578, a value consistent with fixed- and weight-based dosing providing similar control of PK variability. A fixed dose of 200 mg Q3W was investigated in trials based on predicted exposures maintained within the established exposure range in all patients. Mean (% CV, n) AUCss, 6-weeks was 1.87 (37%, 830), 1.38 (38%, 760) and 7.63 (35%, 1405) mg*day/mL in patients receiving 200 mg, 2 mg/kg and 10 mg/kg Q3W pembrolizumab. High-weight patients had the lowest exposures with 200 mg Q3W; however, exposures in this group (>90 kg) were within the range of prior clinical experience at 2 mg/kg Q3W associated with near maximal efficacy.


Doses of 200 mg and 2 mg/kg provide similar exposure distributions with no advantage to either dosing approach with respect to controlling PK variability. These findings suggest that weight-based and fixed-dose regimens are appropriate for pembrolizumab.


Pembrolizumab Fixed dose Flat dose Dosing strategy Clinical dose Exposure-response analysis Population pharmacokinetics analysis

No hay comentarios:

Publicar un comentario